Half Year Report and Appendix 4D 31 December 2025
Released
Released
Announcement PDF
RAD
RADIOPHARM THERANOSTICS
Interim Report:
Half Year Ended
31December2025
Radiopharm Theranostics Limited
Appendix 4D
Half-year report
1. Company details
Name of entity: Radiopharm Theranostics Limited
ABN: 57 647 877 889
Reporting period: For the half-year ended 31 December 2025
Previous period: For the half-year ended 31 December 2024
2. Results for announcement to the market
$
Loss from ordinary activities after tax attributable to the owners of
Radiopharm Theranostics Limited up 44.00% to (26,965,473)
Loss for the half-year attributable to the owners of Radiopharm
Theranostics Limited up 44.00% to (26,965,473)
3. Net tangible assets
31 December
2025
31 December
2024
Cents Cents
Net tangible assets per ordinary security 0.14 0.18
4. Explanation of results
An explanation of the key financial elements contributing to the revenue and result above can be found in the review of
operations and activities included within the directors' report.
5. Distributions
No dividends have been paid or declared by the group for the current financial period. No dividends were paid for the previous
financial period.
6. Changes in controlled entities
During the period ended 31 December 2025. Radiopharm Theranostics increased its ownership in Radiopharm Ventures,
LLC, a joint venture created with The University of Texas M.D. Anderson Cancer Center (MDACC) from 75% to 87.5%.
There have been no other changes in controlled entities during the half-year ended 31 December 2025.
7. Other information required by Listing Rule 4.2A
a. Details of individual and total dividends or distributions and dividend or distribution payments: N/A
b. Details of any dividend or distribution reinvestment plans: N/A
c. Details of associates and joint venture entities: N/A
d. Other information N/A
8. Interim review
The financial statement have been reviewed by the group's independent auditor who has issued an unmodified
opinion.
1
REVIEW OF OPERATIONS & ACTIVITIES
Half-year ended: 31 December 2025
Radiopharm Theranostics Limited is developing a world-class platform of radiopharmaceutical and nuclear
medicine products for both diagnostic and therapeutic uses.
Financial Review
The group reported a loss for the half-year ended 31 December 2025 of $28,243,811 (31 December 2024:
$19,643,011). The increase in net loss for the period is mainly attributable to increased research and development
expenditures aligned with the group’s pipeline.
The group’s net assets increased to $49,940,027 (30 June 2025: $42,871,904). The substantial increase in the
group's net assets is primarily due to the completion of the $35 million placement completed during the half year.
As at 31 December 2025, the group had cash reserves of $34,515,397 (30 June 2025: $29,116,835).
Clinical and Research Developments
18F-RAD 101 – Brain Metastases Imaging
RAD 101, a Fluorine-18 labelled small molecule targeting fatty acid synthase (FASN), continued to deliver clinically
meaningful data in its ongoing U.S. Phase 2b trial during the half year. The study is evaluating the diagnostic
performance of RAD 101 in patients with recurrent brain metastases across a range of solid tumour types, with
the primary endpoint being concordance with MRI imaging.
In December 2025, interim data from the first twelve patients demonstrated that 92% of evaluable participants
achieved concordance with MRI, meeting the study’s primary endpoint. These results are consistent with earlier
Phase 2a findings and further validate the molecule’s ability to detect metabolically active tumour tissue in the
brain. Importantly, RAD 101 has shown the capacity to identify tumour activity in cases where MRI findings are
equivocal, addressing a significant clinical challenge in differentiating true recurrence from treatment-related
changes such as radiation necrosis.
The trial remains on track to complete enrolment in the first quarter of 2026, with topline data anticipated shortly
thereafter. Given its FDA Fast Track designation and the large addressable patient population, over 300,000 new
cases of cerebral metastases diagnosed annually in the United States, the Company is preparing for the potential
initiation of a multi-centre, multi-country Phase 3 registrational study.
177Lu-RAD 202 – HER2-Targeted Radiotherapeutic
RAD 202, a Lutetium-177 labelled nanobody targeting HER2, progressed through its Phase 1 ‘HEAT’ clinical study
in patients with advanced HER2-positive solid tumours, including breast and other cancers where HER2
overexpression is well established as a therapeutic target.
During the period, dosing at the initial 30mCi level was completed. Early clinical data from the first cohort
demonstrated significant tumour uptake in HER2-positive lesions, confirming favourable biodistribution and
target engagement. The safety profile has remained reassuring, with no drug-related adverse events reported to
date.
2
Following review by the independent Data Safety Monitoring Committee, the study advanced to the higher 75mCi
dose level. The Company expects to complete enrolment in the second cohort in the first half of 2026.
RAD 202 represents a differentiated approach to HER2-directed therapy, combining the precision of nanobody
targeting with the cytotoxic potential of radiotherapy. Positive safety and tumour uptake findings support the
potential to move toward later-stage development in selected HER2-positive indications, particularly in patients
who have progressed following existing HER2-targeted therapies.
177Lu-RAD 204 – PD-L1-Targeted Radiotherapeutic
RAD 204, a Lutetium-177 labelled nanobody targeting PD-L1, continued to advance in its Phase 1 study across PD-
L1-driven malignancies, including non-small cell lung cancer, small-cell lung cancer, triple-negative breast cancer,
melanoma, head and neck squamous cell carcinoma and endometrial cancer.
Initial data from the 30mCi cohort demonstrated tumour uptake in PD-L1-positive lesions consistent with
previously reported imaging data, supporting the molecule’s ability to selectively target PD-L1-expressing
tumours. The safety profile has remained favourable, with no drug-related adverse events reported and no dose-
limiting toxicities observed to date.
Encouragingly, two of three patients with late-stage metastatic non-small cell lung cancer in the 30mCi cohort
achieved stable disease for 5.5 months, compared to historical progression-free survival of approximately 3.5
months under standard of care in similar treatment-refractory settings. While early and limited in patient
numbers, this signal supports further dose escalation and exploration of therapeutic benefit.
The second cohort has been completed and, following DSMC approval, the Company has proceeded to a third
cohort at an updated dose level of 90mCi.
Lu177-RV 01 (Betabart) – B7-H3-Targeted Monoclonal Antibody
RV-01 (Betabart), a Lutetium-177 conjugated monoclonal antibody targeting the 4Ig isoform of B7-H3, advanced
from preclinical development into the clinical stage during the period. B7-H3 is an immune checkpoint protein
highly expressed in a range of solid tumours but largely absent from healthy tissue, making it an attractive
therapeutic target in oncology.
In July 2025, RV-01 received Investigational New Drug clearance from the U.S. FDA to initiate a first-in-human
Phase 1 clinical trial. The Company expects to dose the first patients in the first quarter of 2026. Preclinical studies
have demonstrated tumour shrinkage and extended survival in animal models, with a hepatic clearance profile
that may reduce the risk of haematologic toxicity relative to agents with predominant renal excretion.
Tb161-RAD 402 – KLK3-Targeted Radiotherapeutic for Prostate Cancer
RAD 402, a monoclonal antibody targeting KLK3 (prostate-specific antigen) and radiolabelled with Terbium-161,
progressed toward first-in-human evaluation during the period. KLK3 is a well-established biomarker and
therapeutic target in prostate cancer, and Terbium-161 offers potential advantages due to its emission of both
beta particles and conversion electrons, which may enhance tumour cell kill while limiting off-target exposure.
3
In November 2025, RAD 402 received approval from the Bellberry Human Research Ethics Committee in Australia
to initiate a Phase 1 study in patients with metastatic or locally advanced prostate cancer. Preclinical data in
xenograft models demonstrated strong tumour targeting, limited bone and marrow uptake and a favourable
hepatic excretion profile consistent with monoclonal antibody-based radiotherapeutics.
The Company anticipates commencing dosing in the first quarter of 2026.
Ga68-RAD 301 – αvβ6 Integrin-Targeted Imaging in Pancreatic Cancer
RAD 301, a Gallium-68 labelled peptide targeting αvβ6-integrin, continued enrolment in its Phase 1 imaging study
in patients with pancreatic ductal adenocarcinoma. αvβ6-integrin is associated with tumour invasion, metastatic
progression and poorer prognosis, particularly in pancreatic cancer.
During the half year, eight of the planned nine patients were dosed, with initial data from the first six confirming
favourable safety and significant uptake in αvβ6-positive lesions. These findings support the molecule’s specificity
and diagnostic utility.
RAD 301 has previously received FDA Orphan Drug Designation, reinforcing its relevance in a high-mortality
indication with limited effective diagnostic tools.
Corporate Updates
Radiopharm announced the appointment of Mr Bruce Goodwin as a Non-Executive Director, effective 19
November 2025. Mr Goodwin is a highly respected leader in the life sciences sector, bringing over four decades
of experience across global healthcare and biopharmaceutical industries.
He currently serves as a Non-Executive Director across six organisations operating within the healthcare sector,
where he provides strategic guidance and governance expertise. Mr Goodwin’s career includes more than three
decades with the Janssen Pharmaceutical Companies of Johnson & Johnson, during which he held senior
leadership roles across multiple countries and regions. His tenure was marked by a strong record of driving
organisational growth, fostering innovation, and leading high-performing teams in complex, multinational
environments. Mr Goodwin has demonstrated a deep commitment to advancing the life sciences industry. He has
served on industry peak body boards in Australia and Japan, contributing to policy development, regulatory
dialogue, and cross-sector collaboration. He is also regarded for his strategic acumen, global perspective, and
passion for improving health outcomes through innovation, leadership, and effective governance.
In conjunction with this appointment, Mr Phillip Hains and Dr Leila Alland retired from the Board at the 2025
Annual General Meeting. Mr Hains continues in his current roles as Chief Financial Officer and Company Secretary.
During the period, Radiopharm strengthened its scientific and strategic capabilities. Dr Oliver Sartor, an
internationally recognised medical oncologist with deep expertise in radiopharmaceutical therapies and prostate
cancer, was appointed to the Company’s Scientific Advisory Board. His experience in leading multiple pivotal Phase
3 trials and contributing to FDA-approved radiotherapeutics enhances the Company’s clinical development
oversight.
4
The Company also hosted multiple key opinion leader webinars during the September quarter, supporting broader
engagement with the oncology and radiopharmaceutical community and reinforcing its profile as a clinical-stage
developer with a diversified and advancing pipeline.
Post end of half year, Radiopharm increased its ownership in Radiopharm Ventures (a joint venture created in
2022 between MD Anderson Cancer Center and Radiopharm) to 87.5%, consolidating its interest in the joint
venture’s B7-H3 program and associated preclinical assets. This strategic move reflects management’s
prioritisation of high value, differentiated radiotherapeutic programs.
Fundraising Activities
During the period, the Company secured firm commitments to raise approximately A$35 million via an
institutional placement, supported by new and existing Australian and international investors, including strategic
investor Lantheus Holdings. Participants received attaching options that were approved at a subsequent
shareholder meeting.
In addition, a Share Purchase Plan was launched to provide eligible retail shareholders with the opportunity to
participate on equivalent terms, raising a further A$0.4m.
The capital raising strengthens Radiopharm’s ability to progress multiple Phase 1 and Phase 2 programs in parallel,
advance drug manufacturing capabilities, and support regulatory and clinical milestones anticipated through 2026
and beyond.
In December, the Company filed a registration statement on Form F-3 with the U.S. Securities and Exchange
Commission (SEC) to establish an At-the-Market (ATM) facility for the sale of American Depositary Shares (ADSs),
each representing 300 ordinary shares of the Company, on Nasdaq.
The ATM equity facility will provide up to US$18.9 million from Leerink Partners LLC. The Company will control
the placement process, having sole discretion as to whether it uses the ATM, the number of ADSs sold, as well as
the minimum sale price of the ADSs. Such ATM facilities are widely used in the United States and have become
increasingly common in Australia, and the facility will be subject to the ASX Listing Rule framework for share
issuances.
In July 2025, Radiopharm announced it had received its research and development (R&D) tax refund for the 2024
financial year, totalling A$4,485,434, including A$94,559 interest.
For and on behalf of the company,
Riccardo Canevari
CEO and Managing Director
Radiopharm Theranostics Limited
Contents
31 December 2025
5
Directors' report 6
Auditor's independence declaration 8
Statement of profit or loss and other comprehensive income 9
Statement of financial position 10
Statement of changes in equity 11
Statement of cash flows 13
Notes to the financial statements 14
Directors' declaration 25
Independent auditor's review report to the members of Radiopharm Theranostics Limited 26
General information
The financial statements cover Radiopharm Theranostics Limited as a consolidated entity consisting of Radiopharm
Theranostics Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented
in Australian dollars, which is Radiopharm Theranostics Limited's functional and presentation currency.
Radiopharm Theranostics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its
registered office and principal place of business are:
Registered office Principal place of business
Level 3, 62 Lygon Street, Carlton, Victoria 3053 Level 3, 62 Lygon Street, Carlton, Victoria 3053
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report,
which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2026.
Radiopharm Theranostics Limited
Directors' report
31 December 2025
6
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as
the 'consolidated entity') consisting of Radiopharm Theranostics Limited (referred to hereafter as the 'company' or 'parent
entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2025.
Directors
The following persons held office as directors of Radiopharm Theranostics Limited during the financial period and up
to the date of this report.
Mr Paul Hopper
Mr Riccardo Canevari
Mr Ian Turner
Ms Hester Larkin
Mr Noel Donnelly
Mr Bruce Goodwin (appointed 19 November 2025)
Mr Phillip Hains (resigned 20 November 2025)
Dr Leila Alland (resigned 20 November 2025)
Review of Operations & Activities
Information on the financials and operations of the group and its business strategies and prospects is set out in the review of
operations and activities on pages 1 to 4 of this interim financial report.
Significant changes in the state of affairs
On 20 October 2025, Radiopharm Theranostics completed a A$35 million share placement (gross of costs) for the issuance
of 1,179,266,658 ordinary shares. The proceeds of the capital raising was primarily used to fund drug manufacturing, clinical
trials and working capital, extending the funding runway into 2027 and past a number of key milestones.
On 19 November 2025, Radiopharm Theranostics announced the appointment of Mr. Bruce Goodwin as a Non-Executive
Director.
Post end of half year, Radiopharm increased its ownership in Radiopharm Ventures (a joint venture created in 2022 between
MD Anderson Cancer Center and Radiopharm) to 87.5%, consolidating its interest in the joint venture’s B7-H3 program and
associated preclinical assets. This strategic move reflects management’s prioritisation of high value, differentiated
radiotherapeutic programs.
There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.
Matters subsequent to the end of the financial half-year
No matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect,
the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent
financial periods.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
Rounding of amounts
The group is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts in the
directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest
dollar in accordance with the instrument.
Radiopharm Theranostics Limited
Directors' report
31 December 2025
7
This report is made in accordance with a resolution of directors.
On behalf of the directors
___________________________
Mr Paul Hopper
Executive Chairman
27 February 2026
Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222
grantthornton.com.au
ACN-130 913 594
Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. Grant Thornton’
refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as
the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide
partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its
member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term
‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a
scheme approved under Professional Standards Legislation.
Auditor’s Independence Declaration
To the Directors of Radiopharm Theranostics Limited
In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of
Radiopharm Theranostics Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and
belief, there have been:
a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
b no contraventions of any applicable code of professional conduct in relation to the review.
Grant Thornton Audit Pty Ltd
Chartered Accountants
T S Jackman
Partner – Audit & Assurance
Melbourne, 27 February 2026
Radiopharm Theranostics Limited
Statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2025
Consolidated
Note
31 December
2025
31 December
2024
$ $
The above statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
9
Revenue
Revenue from contracts with customers 2 1,385,545 1,383,647
Cost of sales (1,282,463) (1,614,819)
Gross profit 103,082 (231,172)
Other income and expense items 3 4,818,066 1,053,715
Other gains/(losses) 4 (382,725) 235,090
Expenses
General and administrative expenses (8,369,242) (6,342,360)
Research and development (21,315,901) (13,593,037)
Share-based payments expenses (1,523,874) (692,625)
Movement in contingent consideration (1,373,810) 28,060
Operating loss (28,044,404) (19,542,329)
Finance expenses (65,105) 285
Loss before income tax expense (28,109,509) (19,542,044)
Income tax expense (134,302) (100,967)
Loss after income tax expense for the half-year (28,243,811) (19,643,011)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Foreign currency translation 410,892 375,938
Other comprehensive income for the half-year, net of tax 410,892 375,938
Total comprehensive loss for the half-year (27,832,919) (19,267,073)
Loss for the half-year is attributable to:
Non-controlling interest 12 (1,278,338) (917,558)
Owners of Radiopharm Theranostics Limited (26,965,473) (18,725,453)
(28,243,811) (19,643,011)
Total comprehensive income for the half-year is attributable to:
Non-controlling interest 12 (1,278,338) (917,558)
Owners of Radiopharm Theranostics Limited (26,554,581) (18,349,515)
(27,832,919) (19,267,073)
Note Cents Cents
Loss per share for loss attributable to the ordinary equity holders of the group:
Basic/diluted loss per share 15 (1.05) (1.02)
Radiopharm Theranostics Limited
Statement of financial position
As at 31 December 2025
Consolidated
Note
31 December
2025
30 June
2025
$ $
The above statement of financial position should be read in conjunction with the accompanying notes
10
Assets
Current assets
Cash and cash equivalents 34,515,397 29,116,835
Trade and other receivables 5 11,359,430 10,400,060
Other current assets 168,000 337,093
Total current assets 46,042,827 39,853,988
Non-current assets
Property, plant and equipment 49,771 53,466
Intangible assets 8 45,079,291 46,574,422
Total non-current assets 45,129,062 46,627,888
Total assets 91,171,889 86,481,876
Liabilities
Current liabilities
Trade and other payables 6 10,717,015 9,340,993
Other financial liabilities 7 2,986,876 3,421,337
Employee benefit obligations 575,236 450,104
Deferred revenue 1,015,984 1,720,551
Total current liabilities 15,295,111 14,932,985
Non-current liabilities
Other financial liabilities 7 25,936,751 28,676,987
Total non-current liabilities 25,936,751 28,676,987
Total liabilities 41,231,862 43,609,972
Net assets 49,940,027 42,871,904
Equity
Share capital 9 209,935,661 176,558,493
Other equity 11 849,544 849,544
Other reserves 10 13,366,322 13,116,919
Accumulated losses (172,370,980) (145,732,952)
Equity attributable to the owners of Radiopharm Theranostics Limited 51,780,547 44,792,004
Non-controlling interest (1,840,520) (1,920,100)
Total equity 49,940,027 42,871,904
Radiopharm Theranostics Limited
Statement of changes in equity
For the half-year ended 31 December 2025
The above statement of changes in equity should be read in conjunction with the accompanying notes
11
Attributable to owners of
Radiopharm Theranostics Limited
Share
capital
Other
equity
Other
reserves
Accumulated
losses
Non-
controlling
interest
Total
equity
Consolidated $ $ $ $ $ $
Balance at 1 July 2024 100,681,716 849,544 37,930,072 (111,338,770) (769,276) 27,353,286
Loss after income tax expense
for the half-year - - - (18,725,453) (917,558) (19,643,011)
Other comprehensive income for
the half-year, net of tax - - 375,938 - - 375,938
Total comprehensive income
for the half-year - - 375,938 (18,725,453) (917,558) (19,267,073)
Transactions with owners in
their capacity as owners:
Contributions of equity, net of
transaction costs 66,638,719 - (23,885,229) - - 42,753,490
Share-based payments (note
13) 741,400 - - - - 741,400
Issue of options - - 955,055 - - 955,055
Equity-settled payments 219,840 - (231,115) - - (11,275)
Expiration of options - - (2,767,466) 2,767,466 - -
Options forfeited - - (221,170) - - (221,170)
Cancellation of shares to be
issued - - (300,000) - - (300,000)
Increase of ownership in RAD
Ventures - - - (488,544) 488,544 -
Balance at 31 December 2024 168,281,675 849,544 11,856,085 (127,785,301) (1,198,290) 52,003,713
Radiopharm Theranostics Limited
Statement of changes in equity
For the half-year ended 31 December 2025
The above statement of changes in equity should be read in conjunction with the accompanying notes
12
Attributable to owners of
Radiopharm Theranostics Limited
Share
capital
Other
equity
Other
reserves
Accumulated
losses
Non-
controlling
interest
Total
equity
Consolidated $ $ $ $ $ $
Balance at 1 July 2025 176,558,493 849,544 13,116,919 (145,732,952) (1,920,100) 42,871,904
Loss after income tax expense
for the half-year - - - (26,965,473) (1,278,338) (28,243,811)
Other comprehensive income
for the half-year, net of tax - - 410,892 - - 410,892
Total comprehensive income
for the half-year - - 410,892 (26,965,473) (1,278,338) (27,832,919)
Transactions with owners in
their capacity as owners:
Contributions of equity, net of
transaction costs (note 9) 25,727,168 - - - - 25,727,168
Issue of shares for milestone
completion (note 9) 7,650,000 - - - - 7,650,000
Issue of options - - 1,523,874 - - 1,523,874
Expiration of unlisted options
(note 10) - - (1,685,363) 1,685,363 - -
Increase of ownership in RAD
Ventures - - - (1,357,918) 1,357,918 -
Balance at 31 December 2025 209,935,661 849,544 13,366,322 (172,370,980) (1,840,520) 49,940,027
Radiopharm Theranostics Limited
Statement of cash flows
For the half-year ended 31 December 2025
Consolidated
31 December
2025
31 December
2024
$ $
The above statement of cash flows should be read in conjunction with the accompanying notes
13
Cash flows from operating activities
Payments to suppliers (inclusive of GST) (27,420,065) (22,596,082)
Research and development tax incentive tax received 4,485,434 -
Interest received 262,305 379,616
Net cash used in operating activities (22,672,326) (22,216,466)
Cash flows from investing activities
Payments for license fee liabilities and settlement fees (5,311,980) (2,916,715)
Proceeds from disposal of intellectual property - 2,997,592
Net cash from/(used in) investing activities (5,311,980) 80,877
Cash flows from financing activities
Proceeds from issue of shares 35,263,492 45,842,762
Share issue transaction costs (1,825,043) (4,198,440)
Repayment of borrowings - (1,900,000)
Transaction costs related to loans and borrowings - (218,633)
Net cash from financing activities 33,438,449 39,525,689
Net increase in cash and cash equivalents 5,454,143 17,390,100
Cash and cash equivalents at the beginning of the financial half-year 29,116,835 18,575,040
Effects of exchange rate changes on cash and cash equivalents (55,581) 471,798
Cash and cash equivalents at the end of the financial half-year 34,515,397 36,436,938
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2025
14
Note 1. Segments Information
Management has determined, based on the reports reviewed by the chief operating decision maker (CODM) that are used to
make strategic decisions, that the group has one reportable segment being the research, development and commercialisation
of health technologies. As such, the financial information presented in the body of the financial report represents the results
of the Group's sole operating segment. The CODM continues to monitor and review the appropriateness of this segment
determination on a regular basis.
Note 2. Revenue from contracts with customers
Consolidated
31 December
2025
31 December
2024
$ $
Revenue from contracts with customers
Revenue recognised over time 1,385,545 1,383,647
1,385,545 1,383,647
During the period ended 31 December 2024, the group entered into a strategic development services contract with Lantheus
to advance clinical development of innovative radiopharmaceuticals in Australia. For more information in relation to the group's
policy for recognising revenue refer to (vii).
Note 3. Other income and expense items
(a) Other income
31 December
2025
31 December
2024
$ $
Interest income 268,933 379,682
Research and development tax incentive (i) 4,549,133 674,033
4,818,066 1,053,715
(i) R&D tax incentive
The group's research and development activities are eligible under an Australian government tax incentive for eligible
expenditure. Where expenditure is incurred outside of Australia, an 'overseas finding' must be obtained from AusIndustry prior
to any such expenditure being eligible under the scheme. Management has assessed these activities and expenditure to
determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established
that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the period
ended 31 December 2025, the group has included an item in other income of $4,549,133 (2024: $674,033) to recognise
income over the period necessary to match the grant on a systematic basis with the costs that they are intended to
compensate. The assistance received is a direct cash payment from ATO and is not related to any tax liability or income tax
calculation.
Radiopharm Theranostics Limited
Notes to the financial statements
31 December 2025
15
Note 4. Other gains/(losses)
Conso
Share your feedback
Discover